Cargando…

Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations

HIGHLIGHTS: What are the main findings? The levels of IgG1, IgG2, IgG3, and IgG4 are reduced in patients with COPD with acute infectious exacerbations. IgG3 levels are related to the severity of COPD. What are the implications of the main findings? IgGs are important in follow-up studies to assess C...

Descripción completa

Detalles Bibliográficos
Autores principales: Ba Ta, Thang, Tran Viet, Tien, Xuan Nguyen, Kien, Hai Nguyen, Cong, Ngoc Vu, Hoan, Dinh Le, Tuan, Tien Nguyen, Son, Khac Dong, Hung, Kim Thi Pham, Nhung, Ngoc Dao, Bang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774113/
https://www.ncbi.nlm.nih.gov/pubmed/36547011
http://dx.doi.org/10.3390/arm90060056
_version_ 1784855329538834432
author Ba Ta, Thang
Tran Viet, Tien
Xuan Nguyen, Kien
Hai Nguyen, Cong
Ngoc Vu, Hoan
Dinh Le, Tuan
Tien Nguyen, Son
Khac Dong, Hung
Kim Thi Pham, Nhung
Ngoc Dao, Bang
author_facet Ba Ta, Thang
Tran Viet, Tien
Xuan Nguyen, Kien
Hai Nguyen, Cong
Ngoc Vu, Hoan
Dinh Le, Tuan
Tien Nguyen, Son
Khac Dong, Hung
Kim Thi Pham, Nhung
Ngoc Dao, Bang
author_sort Ba Ta, Thang
collection PubMed
description HIGHLIGHTS: What are the main findings? The levels of IgG1, IgG2, IgG3, and IgG4 are reduced in patients with COPD with acute infectious exacerbations. IgG3 levels are related to the severity of COPD. What are the implications of the main findings? IgGs are important in follow-up studies to assess COPD exacerbations. This study could be a suggestion for conducting future studies using immunotherapy to treat COPD. ABSTRACT: Introduction: Despite the theoretical importance of serum immunoglobulin (Ig) in the outcome of COPD exacerbations, the existing evidence for this has not been enough. This study was performed to evaluate changes in serum Ig levels and their relationship with outcomes of acute infectious exacerbations in patients with COPD. Methods: The prospective study was conducted at Military Hospital 103 from August 2017 to April 2019. Group D patients with COPD with infectious exacerbation were selected for participation in the study. The control group consisted of 30 healthy people. The patients were provided clinical examination and laboratory service; simultaneously, we measured their serum Ig levels (total IgG, IgG1, IgG2, IgG3, IgG4) at two time points: at admission (T1) and the final health outcome (T2). Results: The median levels of total IgG in patients at times T1 and T2 were significantly lower compared with those in the healthy group (1119.3 mg/dL and 1150.6 mg/dL compared with 2032.2 mg/dL) (p < 0.001). Regarding changes among IgG subclasses, the IgG1, IgG3, and IgG4 levels measured at T1 and T2 were reduced significantly compared with the control group (p < 0.05); the IgG3 levels at T1 were significantly higher than those at T2. IgG3 levels in patients with life-threatening exacerbations were significantly lower than the remaining ones (24.6 (26.8–155.5) mg/dL and 25.6 (29.5–161.2) mg/dL, respectively, p = 0.023). Conclusions: In group D patients with COPD with infectious exacerbations, there was a decrease in the serum IgG, IgG1, IgG3, and IgG4 levels. IgG3 levels were associated with the severity of COPD exacerbation.
format Online
Article
Text
id pubmed-9774113
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97741132022-12-23 Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations Ba Ta, Thang Tran Viet, Tien Xuan Nguyen, Kien Hai Nguyen, Cong Ngoc Vu, Hoan Dinh Le, Tuan Tien Nguyen, Son Khac Dong, Hung Kim Thi Pham, Nhung Ngoc Dao, Bang Adv Respir Med Article HIGHLIGHTS: What are the main findings? The levels of IgG1, IgG2, IgG3, and IgG4 are reduced in patients with COPD with acute infectious exacerbations. IgG3 levels are related to the severity of COPD. What are the implications of the main findings? IgGs are important in follow-up studies to assess COPD exacerbations. This study could be a suggestion for conducting future studies using immunotherapy to treat COPD. ABSTRACT: Introduction: Despite the theoretical importance of serum immunoglobulin (Ig) in the outcome of COPD exacerbations, the existing evidence for this has not been enough. This study was performed to evaluate changes in serum Ig levels and their relationship with outcomes of acute infectious exacerbations in patients with COPD. Methods: The prospective study was conducted at Military Hospital 103 from August 2017 to April 2019. Group D patients with COPD with infectious exacerbation were selected for participation in the study. The control group consisted of 30 healthy people. The patients were provided clinical examination and laboratory service; simultaneously, we measured their serum Ig levels (total IgG, IgG1, IgG2, IgG3, IgG4) at two time points: at admission (T1) and the final health outcome (T2). Results: The median levels of total IgG in patients at times T1 and T2 were significantly lower compared with those in the healthy group (1119.3 mg/dL and 1150.6 mg/dL compared with 2032.2 mg/dL) (p < 0.001). Regarding changes among IgG subclasses, the IgG1, IgG3, and IgG4 levels measured at T1 and T2 were reduced significantly compared with the control group (p < 0.05); the IgG3 levels at T1 were significantly higher than those at T2. IgG3 levels in patients with life-threatening exacerbations were significantly lower than the remaining ones (24.6 (26.8–155.5) mg/dL and 25.6 (29.5–161.2) mg/dL, respectively, p = 0.023). Conclusions: In group D patients with COPD with infectious exacerbations, there was a decrease in the serum IgG, IgG1, IgG3, and IgG4 levels. IgG3 levels were associated with the severity of COPD exacerbation. MDPI 2022-11-23 /pmc/articles/PMC9774113/ /pubmed/36547011 http://dx.doi.org/10.3390/arm90060056 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ba Ta, Thang
Tran Viet, Tien
Xuan Nguyen, Kien
Hai Nguyen, Cong
Ngoc Vu, Hoan
Dinh Le, Tuan
Tien Nguyen, Son
Khac Dong, Hung
Kim Thi Pham, Nhung
Ngoc Dao, Bang
Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations
title Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations
title_full Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations
title_fullStr Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations
title_full_unstemmed Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations
title_short Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations
title_sort changes in serum immunoglobulin g subclasses during the treatment of patients with chronic obstructive pulmonary disease with infectious exacerbations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774113/
https://www.ncbi.nlm.nih.gov/pubmed/36547011
http://dx.doi.org/10.3390/arm90060056
work_keys_str_mv AT batathang changesinserumimmunoglobulingsubclassesduringthetreatmentofpatientswithchronicobstructivepulmonarydiseasewithinfectiousexacerbations
AT tranviettien changesinserumimmunoglobulingsubclassesduringthetreatmentofpatientswithchronicobstructivepulmonarydiseasewithinfectiousexacerbations
AT xuannguyenkien changesinserumimmunoglobulingsubclassesduringthetreatmentofpatientswithchronicobstructivepulmonarydiseasewithinfectiousexacerbations
AT hainguyencong changesinserumimmunoglobulingsubclassesduringthetreatmentofpatientswithchronicobstructivepulmonarydiseasewithinfectiousexacerbations
AT ngocvuhoan changesinserumimmunoglobulingsubclassesduringthetreatmentofpatientswithchronicobstructivepulmonarydiseasewithinfectiousexacerbations
AT dinhletuan changesinserumimmunoglobulingsubclassesduringthetreatmentofpatientswithchronicobstructivepulmonarydiseasewithinfectiousexacerbations
AT tiennguyenson changesinserumimmunoglobulingsubclassesduringthetreatmentofpatientswithchronicobstructivepulmonarydiseasewithinfectiousexacerbations
AT khacdonghung changesinserumimmunoglobulingsubclassesduringthetreatmentofpatientswithchronicobstructivepulmonarydiseasewithinfectiousexacerbations
AT kimthiphamnhung changesinserumimmunoglobulingsubclassesduringthetreatmentofpatientswithchronicobstructivepulmonarydiseasewithinfectiousexacerbations
AT ngocdaobang changesinserumimmunoglobulingsubclassesduringthetreatmentofpatientswithchronicobstructivepulmonarydiseasewithinfectiousexacerbations